Imperial College London
Portrait Picture

DrGeorgiosNteliopoulos

Faculty of Medicine, Department of Surgery & Cancer

Research Associate Biomarker
 
 
 
//

Contact

 

georgios.nteliopoulos04

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Reebye:2016:10.1038/mtna.2013.23,
author = {Reebye, V and Saetrom, P and Mintz, PJ and Rossi, JJ and Kasahara, N and Nteliopoulos, G and Nicholls, J and Haoudi, A and Gordon, M and Habib, NA},
doi = {10.1038/mtna.2013.23},
journal = {MOLECULAR THERAPY-NUCLEIC ACIDS},
title = {A short-activating RNA oligonucleotide targeting the islet beta-cell transcriptional factor MafA in CD34(+) cells},
url = {http://dx.doi.org/10.1038/mtna.2013.23},
volume = {2},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Upon functional loss of insulin producing islet β-cells, some patients with diabetes become dependent on life-long insulin supplementation therapy. Bioengineering surrogate insulin producing cells is an alternative replacement strategy. We have developed a novel approach using short-activating RNA oligonucleotides to differentiate adult human CD34+ cells into insulin-secreting cells. By transfecting RNA to increase transcript levels of the master regulator of insulin biosynthesis, v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), several pancreatic endodermal genes were upregulated during the differentiation procedure. These included Pancreatic and duodenal homeobox gene-1 (PDX1), Neurogenin 3, NeuroD, and NK6 homeobox 1 (NKx6-1). Differentiated CD34+ cells also expressed glucokinase, glucagon-like peptide 1 receptor (GLP1R), sulfonylurea receptor-1 (SUR1) and phogrin'all essential for glucose sensitivity and insulin secretion. The differentiated cells appropriately processed C-peptide and insulin in response to increasing glucose stimulation as shown by enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting analysis, western blotting, and immunofluorescence staining. We provide a new approach using short-activating RNA in developing insulin producing surrogate cells for treating diabetes.
AU  - Reebye,V
AU  - Saetrom,P
AU  - Mintz,PJ
AU  - Rossi,JJ
AU  - Kasahara,N
AU  - Nteliopoulos,G
AU  - Nicholls,J
AU  - Haoudi,A
AU  - Gordon,M
AU  - Habib,NA
DO  - 10.1038/mtna.2013.23
PY  - 2016///
SN  - 2162-2531
TI  - A short-activating RNA oligonucleotide targeting the islet beta-cell transcriptional factor MafA in CD34(+) cells
T2  - MOLECULAR THERAPY-NUCLEIC ACIDS
UR  - http://dx.doi.org/10.1038/mtna.2013.23
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000332466500002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/45633
VL  - 2
ER  -
Download